Korawit Juprasertporn: Call for Papers – Thrombosis and Antithrombotic Therapy
Korawit Juprasertporn, Section Managing Editor at MDPI, shared a post on LinkedIn:
“Call for Papers – Journal of Clinical Medicine (JCM) MDPI
Cutting-Edge research on Thrombosis and Antithrombotic Therapy
This Special Issue is led by Dr. Sina Rashedi, dedicated to advancing research on thrombosis and antithrombotic therapy.
This rapidly evolving field that continues to shape modern cardiovascular and vascular medicine.
Thrombotic disorders remain a leading cause of morbidity and mortality worldwide, contributing to conditions such as myocardial infarction, ischemic stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE).
While remarkable progress has been made in anticoagulant and antiplatelet therapies, achieving the optimal balance between thrombosis prevention and bleeding risk remains a major clinical challenge.
We invite original research, comprehensive reviews, clinical studies, and expert perspectives that provide new insights into the prevention, diagnosis, and treatment of thrombotic diseases and improve patient outcomes.
Submission Deadline: 1 June 2027.”

Stay updated with Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A